[Prostatic acid phosphatase and prostatic specific antigen measured by immunoenzyme assay].
Prostatic acid phosphatase (PAP) and prostatic specific antigen (PA) were determined with a Cetus test kit (California, USA) for prostatic cancer and others. Abnormal values of PAP in untreated prostatic cancer were found in 0, 0, 50, 50, 0, 73% of stage A1, A2, CpN0, CNX, D1 and D2 cases, respectively, and those of PA were found in 25, 0, 50, 100, 100, 100% of the same stages, respectively. Grade was not related to the level of PAP or PA. Prostatic hypertrophy showed increased values of PAP and PA in 11.1% and 7.4%, respectively. The levels of PAP were not correlated to those of PA. Endocrine treatment decreased the elevated values of PAP and PA in 60% of the cases. Most of the PAP and PA levels in the cases controlled under endocrine therapy were within normal values, but after relapse most showed elevated levels.
D000135:Acid Phosphatase / Q000032:analysis*; D000328:Adult; D000941:Antigens / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D011467:Prostate / Q000201:enzymology*; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis; D011933:Reagent Kits, Diagnostic
D000941:Antigens; D011933:Reagent Kits, Diagnostic; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen